A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome

Clinical trial NCT04078386 · COMPLETED

Trial details

NCT number: NCT04078386
Sponsor: RemeGen Co., Ltd.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Primary Sjögren's Syndrome

Start date: 2019-11-21
Primary completion: 2021-06-23
Enrollment: 42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.